Investment giant advises 'conservative' allocation to digital assets for certain clients, signaling growing mainstream acceptance.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
The pharmaceutical giant is now considered one of Morningstar's highest-conviction undervalued stocks, citing a robust pipeline and strategic acquisitions.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.
Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
Institutional demand and economic uncertainty fuel the historic rally in the world's largest cryptocurrency, pushing the market into a bullish frenzy.
Pharmaceuticals, heavy trucks, and furniture targeted in a move that could spark fresh inflation fears and impact corporate profits.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.